Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1505–1511. doi: 10.1128/aac.39.7.1505

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.

S L Kang 1, M J Rybak 1
PMCID: PMC162771  PMID: 7492094

Abstract

The bactericidal activity and emergence of resistance to RP 59500 (quinupristin/dalfopristin) when it was administered alone and in combination with vancomycin against fibrin clots that have been infected with methicillin-susceptible Staphylococcus aureus ATCC 25923 or methicillin-resistant S. aureus (MRSA) 67 were evaluated in an in vitro pharmacodynamic infected fibrin clot model. Fibrin clots were infected with S. aureus to achieve an inoculum of approximately 10(9) CFU/g. Antibiotics were administered to simulate pharmacokinetics in humans: RP 59500 (7.5 mg/kg of body weight) every 8 h and vancomycin (15 mg/kg) every 12 h over 72 h. Preliminary test tube time-kill experiments with an inoculum of approximately 10(5) CFU/ml suggested that RP 59500 was more rapid in achieving a 99.9% reduction in the number of CFU per milliliter than vancomycin against ATCC 25923 (6.94 versus 24 h; P = 0.0003) and MRSA 67 (6.77 versus 17.03 h; P = 0.004). At a higher inoculum (approximately 10(8) CFU/ml), 99.9% kill was achieved only with the combination regimen against ATCC 25923 and MRSA 67 (10.9 and 10.5 h, respectively), with total reductions of 6.35 and 6.33 log10 CFU/ml over 24 h, respectively. In the fibrin clot model, RP 59500 was more effective than vancomycin in reducing organism titers over 72 h. In the fibrin clot model, the most optimal therapy was the combination regimen.

Full Text

The Full Text of this article is available as a PDF (340.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aumercier M., Bouhallab S., Capmau M. L., Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):9–14. doi: 10.1093/jac/30.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  2. Bayer A. S. Infective endocarditis. Clin Infect Dis. 1993 Sep;17(3):313–322. doi: 10.1093/clinids/17.3.313. [DOI] [PubMed] [Google Scholar]
  3. Bergeron M. G., Robert J., Beauchamp D. Pharmacodynamics of antibiotics in fibrin clots. J Antimicrob Chemother. 1993 May;31 (Suppl 500):113–136. doi: 10.1093/jac/31.suppl_d.113. [DOI] [PubMed] [Google Scholar]
  4. Blaser J. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):125–130. doi: 10.1093/jac/15.suppl_a.125. [DOI] [PubMed] [Google Scholar]
  5. Bouanchaud D. H. In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):95–99. doi: 10.1093/jac/30.suppl_a.95. [DOI] [PubMed] [Google Scholar]
  6. Chambers H. F. Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):117–122. doi: 10.1093/jac/30.suppl_a.117. [DOI] [PubMed] [Google Scholar]
  7. Chandrasekar P. H., Crane L. R., Bailey E. J. Comparison of the activity of antibiotic combinations in vitro with clinical outcome and resistance emergence in serious infection by Pseudomonas aeruginosa in non-neutropenic patients. J Antimicrob Chemother. 1987 Mar;19(3):321–329. doi: 10.1093/jac/19.3.321. [DOI] [PubMed] [Google Scholar]
  8. Collins L. A., Malanoski G. J., Eliopoulos G. M., Wennersten C. B., Ferraro M. J., Moellering R. C., Jr In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms. Antimicrob Agents Chemother. 1993 Mar;37(3):598–601. doi: 10.1128/aac.37.3.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cremieux A. C., Carbon C. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditis. Antimicrob Agents Chemother. 1992 Oct;36(10):2069–2074. doi: 10.1128/aac.36.10.2069. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cremieux A. C., Maziere B., Vallois J. M., Ottaviani M., Azancot A., Raffoul H., Bouvet A., Pocidalo J. J., Carbon C. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis. 1989 May;159(5):938–944. doi: 10.1093/infdis/159.5.938. [DOI] [PubMed] [Google Scholar]
  11. Cremieux A. C., Vallois J. M., Maziere B., Ottaviani M., Bouvet A., Carbon C., Pocidalo J. J. 3H-spiramycin penetration into fibrin vegetations in an experimental model of streptococcal endocarditis. J Antimicrob Chemother. 1988 Jul;22 (Suppl B):127–133. doi: 10.1093/jac/22.supplement_b.127. [DOI] [PubMed] [Google Scholar]
  12. Crémieux A. C., Mazière B., Vallois J. M., Ottaviani M., Bouvet A., Pocidalo J. J., Carbon C. Ceftriaxone diffusion into cardiac fibrin vegetation. Qualitative and quantitative evaluation by autoradiography. Fundam Clin Pharmacol. 1991;5(1):53–60. doi: 10.1111/j.1472-8206.1991.tb00701.x. [DOI] [PubMed] [Google Scholar]
  13. Duval J. Evolution and epidemiology of MLS resistance. J Antimicrob Chemother. 1985 Jul;16 (Suppl A):137–149. doi: 10.1093/jac/16.suppl_a.137. [DOI] [PubMed] [Google Scholar]
  14. Etienne S. D., Montay G., Le Liboux A., Frydman A., Garaud J. J. A phase I, double-blind, placebo-controlled study of the tolerance and pharmacokinetic behaviour of RP 59500. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):123–131. doi: 10.1093/jac/30.suppl_a.123. [DOI] [PubMed] [Google Scholar]
  15. Fantin B., Leclercq R., Ottaviani M., Vallois J. M., Maziere B., Duval J., Pocidalo J. J., Carbon C. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother. 1994 Mar;38(3):432–437. doi: 10.1128/aac.38.3.432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fass R. J. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother. 1991 Mar;35(3):553–559. doi: 10.1128/aac.35.3.553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fekety R. Vancomycin. Med Clin North Am. 1982 Jan;66(1):175–181. doi: 10.1016/s0025-7125(16)31451-1. [DOI] [PubMed] [Google Scholar]
  18. Goffic F. L., Capmau M. L., Bonnet D., Cerceau C., Soussy C., Dublanchet A., Duval J. Plasmid-mediated pristinamycin resistance. PAC IIA: a new enzyme which modifies pristinamycin IIA. J Antibiot (Tokyo) 1977 Aug;30(8):665–669. doi: 10.7164/antibiotics.30.665. [DOI] [PubMed] [Google Scholar]
  19. Herrmann M., Lai Q. J., Albrecht R. M., Mosher D. F., Proctor R. A. Adhesion of Staphylococcus aureus to surface-bound platelets: role of fibrinogen/fibrin and platelet integrins. J Infect Dis. 1993 Feb;167(2):312–322. doi: 10.1093/infdis/167.2.312. [DOI] [PubMed] [Google Scholar]
  20. Leclercq R., Nantas L., Soussy C. J., Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide-lincosamide-streptogramin antibiotics. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):67–75. doi: 10.1093/jac/30.suppl_a.67. [DOI] [PubMed] [Google Scholar]
  21. Levine D. P., Fromm B. S., Reddy B. R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991 Nov 1;115(9):674–680. doi: 10.7326/0003-4819-115-9-674. [DOI] [PubMed] [Google Scholar]
  22. Markowitz N., Quinn E. L., Saravolatz L. D. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med. 1992 Sep 1;117(5):390–398. doi: 10.7326/0003-4819-117-5-390. [DOI] [PubMed] [Google Scholar]
  23. McGrath B. J., Kang S. L., Kaatz G. W., Rybak M. J. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob Agents Chemother. 1994 Sep;38(9):2034–2040. doi: 10.1128/aac.38.9.2034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Megran D. W. Enterococcal endocarditis. Clin Infect Dis. 1992 Jul;15(1):63–71. doi: 10.1093/clinids/15.1.63. [DOI] [PubMed] [Google Scholar]
  25. Moellering R. C., Jr Pharmacokinetics of vancomycin. J Antimicrob Chemother. 1984 Dec;14 (Suppl 500):43–52. doi: 10.1093/jac/14.suppl_d.43. [DOI] [PubMed] [Google Scholar]
  26. Mortara L. A., Bayer A. S. Staphylococcus aureus bacteremia and endocarditis. New diagnostic and therapeutic concepts. Infect Dis Clin North Am. 1993 Mar;7(1):53–68. [PubMed] [Google Scholar]
  27. Nougayrede A., Berthaud N., Bouanchaud D. H. Post-antibiotic effects of RP 59500 with Staphylococcus aureus. J Antimicrob Chemother. 1992 Jul;30 (Suppl A):101–106. doi: 10.1093/jac/30.suppl_a.101. [DOI] [PubMed] [Google Scholar]
  28. Rand K. H., Houck H. J., Brown P., Bennett D. Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother. 1993 Mar;37(3):613–615. doi: 10.1128/aac.37.3.613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Simon H. J., Yin E. J. Microbioassay of antimicrobial agents. Appl Microbiol. 1970 Apr;19(4):573–579. doi: 10.1128/am.19.4.573-579.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Small P. M., Chambers H. F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun;34(6):1227–1231. doi: 10.1128/aac.34.6.1227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Thompson D. F., Letassy N. A., Thompson G. D. Fibrin glue: a review of its preparation, efficacy, and adverse effects as a topical hemostat. Drug Intell Clin Pharm. 1988 Dec;22(12):946–952. doi: 10.1177/106002808802201203. [DOI] [PubMed] [Google Scholar]
  32. Turcotte A., Bergeron M. G. Pharmacodynamic interaction between RP 59500 and gram-positive bacteria infecting fibrin clots. Antimicrob Agents Chemother. 1992 Oct;36(10):2211–2215. doi: 10.1128/aac.36.10.2211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wu T., Yeaman M. R., Bayer A. S. In vitro resistance to platelet microbicidal protein correlates with endocarditis source among bacteremic staphylococcal and streptococcal isolates. Antimicrob Agents Chemother. 1994 Apr;38(4):729–732. doi: 10.1128/aac.38.4.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Yeaman M. R., Norman D. C., Bayer A. S. Staphylococcus aureus susceptibility to thrombin-induced platelet microbicidal protein is independent of platelet adherence and aggregation in vitro. Infect Immun. 1992 Jun;60(6):2368–2374. doi: 10.1128/iai.60.6.2368-2374.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES